Multimodal Cardiovascular and Hepatic Population Imaging

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-15

Study Completion Date

2033-03-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Medical imaging is increasingly important for understanding diseases, detecting them early, and personalizing treatments. New imaging techniques, which can measure processes in the body without surgery, are opening the door to a more precise approach to medicine. Instead of relying on general probabilities, this technology allows us to analyze specific factors in a person's health, leading to better predictions and targeted treatments. One key challenge in medicine today is reducing "residual individual risk"-the remaining health risks that current treatments don't fully address. This involves understanding how factors like age, sex, genetics, and environment affect our health, particularly when it comes to conditions like heart and liver disease. By using imaging to distinguish between normal aging and disease, we can better assess individual health risks.

The current project will create a large collection of medical images linked with health data from a broad population across France. Using advanced, non-invasive techniques such as MRI and ultrasound, researchers will analyze the heart, blood vessels, and liver in detail, considering factors like gender and health risk profiles. This will help improve our understanding of these diseases, which are often silent and not well understood, providing direct benefits to the participants. Ultimately, the goal is to optimize imaging technologies for large-scale studies, which will help enhance early detection and prevention for everyone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Etiological DiagnOsis of caRdiac Diseases Based on echoCardiograpHIc Images and Clinical Data.

NCT05942729

Hypertension Arterial Hypokinetic Cardiomyopathies +1 more

RECRUITING

Evaluation of Left Ventricular Ejection Fraction Using an Accelerated Cardiac Cine-MRI Sequence With Deep Learning-based Image Reconstructions

NCT07061821

Left Ventricular Ejection Fraction Cardiac Magnetic Resonance Imaging Deep Learning +2 more

RECRUITING NA

Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19

NCT04320017

COVID-19 Myocardial Injury Myocarditis

COMPLETED

Multiparametric MRI Assessment of Atrial Heart Disease as a Predictor of Atrial Fibrillation After Myocardial Revascularization Surgery

NCT04657835

Postoperative Atrial Fibrillation

NOT_YET_RECRUITING NA

Evaluation of Left Ventricular Volumes by Real-Time 3-Dimensional Echocardiography

NCT00001740

Heart Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers Imaging Evaluation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Constances volunteers

The 2400 volunteers will be stratifed according to age in decades from 20 to 80 years of age and matched 1:1 male:female.

Imaging examinations

Intervention Type RADIATION

* Cardiovascular MRI
* Hepatic MRI
* Hepatic ultrasound

Paramedical examinations

Intervention Type OTHER

* Urinary pregnancy test for women of childbearing age.
* Blood sample for cardiometabolism profiling
* Blood samples for biobanking (according to the information and consent form)
* Impedancemetry
* AGE reader: combined non-invasive measurement of aging and accumulation of glycated proteins in the subcutaneous tissue will be performed with a CE-marked device.

Medical examination

Intervention Type OTHER

* Review of risk factors
* Review of previous history
* Recording of current medication (dci, dose, start date)
* Recording of medication in the last 6 months and discontinued since (dci, dose, start date)

Echocardiography

Intervention Type OTHER

Echocardiography including: 12-lead digital ECG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Imaging examinations

* Cardiovascular MRI
* Hepatic MRI
* Hepatic ultrasound

Intervention Type RADIATION

Paramedical examinations

* Urinary pregnancy test for women of childbearing age.
* Blood sample for cardiometabolism profiling
* Blood samples for biobanking (according to the information and consent form)
* Impedancemetry
* AGE reader: combined non-invasive measurement of aging and accumulation of glycated proteins in the subcutaneous tissue will be performed with a CE-marked device.

Intervention Type OTHER

Medical examination

* Review of risk factors
* Review of previous history
* Recording of current medication (dci, dose, start date)
* Recording of medication in the last 6 months and discontinued since (dci, dose, start date)

Intervention Type OTHER

Echocardiography

Echocardiography including: 12-lead digital ECG

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participation to the Constances cohort
* Age ≥ 20 years
* No overt cardiovascular or hepatic disease or related symptoms
* No known family or personal genetic disease
* Affiliation with a social security scheme or beneficiary of such a scheme.
* Agreement to sign the consent

Exclusion Criteria

* Renal function impairment with GFR \< 60 mL/min/1.73m2
* Deprived of liberty or persons subject to a legal protection measure (under guardianship or trusteeship)
* People with contraindications to MRI (claustrophobia, presence of metallic elements…)
* Pregnant or breastfeeding woman (pregnancy urinary test before inclusion for women of childbearing age).

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes